{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lee A"],"funding":["National Institute of Allergy and Infectious Diseases","National Institute of Allergy and Infectious Diseases (NIAID)","NIAID NIH HHS","Ralph and Marian Falk Medical Research Catalyst Award","National Science Foundation"],"pagination":["85"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12853802"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(1)"],"pubmed_abstract":["Therapies for type 2 diabetes primarily target hyperglycemia; however, complications are also triggered by advanced glycation end products (AGEs). We hypothesize that the anti-diabetic efficacy of insulin-like growth factor-binding protein 4 (IGFBP4) is enhanced when it assembles with a specific amino acid compound-2 (AAC2) into nanostructures. Their effects were examined in vitro and in ob/ob mice treated for 30 days with the AAC2-IGFBP4 complex or its individual components. IGFBP4-mediated glucose uptake in human and mouse preadipocytes was enhanced by complex formation with AAC2. This complex was confirmed by Fourier-transform mid-infrared spectroscopy, electrophoresis, and AFM. In ob/ob mice, the complex prolonged IGFBP4 circulation and amplified the effects of the individual component"],"journal":["Journal of nanobiotechnology"],"pubmed_title":["Bidirectional regulation of liver sinusoidal clearance by amino acid nanofibers and IGFBP4 complex: effects on HbA1c."],"pmcid":["PMC12853802"],"funding_grant_id":["AI170880","R56 AI170880","CHE-2106924"],"pubmed_authors":["Castelli SL","Yu L","Noria SF","Ortiz M","Kowdley D","Needleman BJ","Rodriguez-Saona L","Lee A","Sellers P","Parquette JR","Pokharel B","Leung JH","Taneja S","Ganesan LP","Ziouzenkova O"],"additional_accession":[]},"is_claimable":false,"name":"Bidirectional regulation of liver sinusoidal clearance by amino acid nanofibers and IGFBP4 complex: effects on HbA1c.","description":"Therapies for type 2 diabetes primarily target hyperglycemia; however, complications are also triggered by advanced glycation end products (AGEs). We hypothesize that the anti-diabetic efficacy of insulin-like growth factor-binding protein 4 (IGFBP4) is enhanced when it assembles with a specific amino acid compound-2 (AAC2) into nanostructures. Their effects were examined in vitro and in ob/ob mice treated for 30 days with the AAC2-IGFBP4 complex or its individual components. IGFBP4-mediated glucose uptake in human and mouse preadipocytes was enhanced by complex formation with AAC2. This complex was confirmed by Fourier-transform mid-infrared spectroscopy, electrophoresis, and AFM. In ob/ob mice, the complex prolonged IGFBP4 circulation and amplified the effects of the individual component","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-16T07:09:53.101Z","creation":"2026-06-16T03:09:56.157Z"},"accession":"S-EPMC12853802","cross_references":{"pubmed":["41454387"],"doi":["10.1186/s12951-025-03943-5"]}}